Skip to main content
. 2020 May 28;100(10):5722. doi: 10.2340/00015555-3463

Fig. 1.

Fig. 1

Total annual costs of skin tumours (i.e. benign, in situ and malignant) for drugs and medical specialist care, vs the number of unique patients, 2007–2017. The relative trough level in 2015 was caused by shortening of the Diagnosis Related Group duration in 2015, causing artificially lower costs.